Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
2017 · The Lancet Neurology · 764 citations
https://doi.org/10.1016/s1474-4422(17)30369-1